OVERVIEW

Oncology Briefings™: Cases and Considerations in the Treatment of Hepatocellular Carcinoma is organized by Physicians' Education Resource, LLC (PER).

Release Date: July 31, 2019
Expiration Date: July 31, 2020

Target Audience:
This educational activity is directed toward an international audience of medical oncologists who treat or manage patients with HCC. Nurse practitioners, nurses, physician assistants, and other healthcare professionals involved in the treatment and management of patients with HCC are also invited to participate.

Accreditation/Credit Designation:
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
This continuing medical education (CME)-certified online activity, “Oncology Briefings™: Cases and Considerations in the Treatment of Hepatocellular Carcinoma,” is an online interactive monograph that provides an overview of etiologic factors in hepatocellular carcinoma (HCC), the implications of a growing understanding of pathophysiologic considerations as they relate to diagnosis and treatment, and treatment options available for HCC. Arndt Vogel, MD, PhD, discusses current and emerging treatment options for the treatment of HCC, emphasizes the keys to managing adverse events (AEs), and provides strategies to ensure the provision of timely and effective sequencing of therapy to optimize patient outcomes.

Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Explain the etiologic factors in HCC and the implications of a growing understanding of these pathophysiologic considerations as they relate to diagnosis and treatment.
• Detail the biologic and mechanistic rationales underlying the use of tyrosine kinase inhibitors, checkpoint inhibitors, and other treatment modalities in HCC.
• Review efficacy and safety data from the latest practice-changing clinical trials in HCC.
• Indicate appropriate treatment strategies in HCC to ensure the provision of timely and effective sequencing of therapy to optimize patient outcomes.